A Study of Galcanezumab (LY2951742) in Adults With Treatment-Resistant Migraine
Clinical trial NCT03559257 · COMPLETED
Trial details
- NCT number
- NCT03559257
- Sponsor
- Eli Lilly and Company
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2018-07-31
- Primary completion
- 2019-06-19
- Enrollment
- 463
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.